Alan W. Partin
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alan W. Partin.
Urology | 1994
Alan W. Partin; Charles R. Pound; Jay D. Pearson; J. Quentin Clemens; Patricia Landis; Jonathan I. Epstein; H. Ballentine Carter; Patrick C. Walsh
OBJECTIVE Serum prostate-specific antigen (PSA) values are most useful for prediction of disease recurrence after surgery. It is unknown whether a detectable PSA level after surgery indicates a local recurrence potentially benefiting from pelvic irradiation or distant metastases requiring hormonal treatment. METHODS We analyzed postoperative rate of change of serum PSA levels as a predictor of local versus distant disease recurrence after radical prostatectomy. Between 1982 and 1991, 1,058 men underwent radical prostatectomy for localized prostate cancer and follow-up consisted of determining serum PSA levels and digital rectal examinations. Clinical follow-up of 542 men for four or more years and 78 men for eight or more years yielded ten-year actuarial disease recurrence rates of 4 percent for local recurrence, 8 percent for distant metastases, and 23 percent for an isolated elevation of serum PSA level only. Fifty-one patients with isolated elevations of PSA levels only were followed expectantly until they were diagnosed with either local or distant metastases. RESULTS A linear mixed effects regression analysis was used to model these data. Using these models, the time to a serum PSA level of 0.5 ng/mL, the PSA level one year following surgery, pathologic stage, Gleason sum, and the rate of change of PSA (PSA velocity [PSAV]) were tested as predictors of local versus distant metastases. A combination of PSAV, pathologic stage, and Gleason grade best distinguished local from distant metastases. CONCLUSIONS These data suggest that PSAV in men with an isolated elevation of PSA levels following radical prostatectomy might aid in clinical decision making.
Urologic Clinics of North America | 1993
Alan W. Partin; Charles R. Pound; Clemens Jq; Jonathan I. Epstein; Patrick C. Walsh
Archive | 2012
Edward M. Schaeffer; Alan W. Partin; Herbert Lepor; Patrick C. Walsh
Biomedical Research and Clinical Practice | 2017
Xiaoju Wang; Jason Hafron; Stephen J. Freedland; Heng Yu; Alice Juang; Doris Vuong; Sandy Kamer; Luis Carbonell; Sharat Singh; Jim Arthurs; Jeanne Ohrnberger; Amanda L Fish; Kristopher Kapphahn; Alan W. Partin
Archive | 1997
Herbert Ballentine Carter; Daniel W. Chan; Alan W. Partin; Albert A. Luderer; Grant D. Carlson; Robert P. Thiel; Jay D. Pearson
Archive | 2015
Steven P. Rowe; Kenneth L. Gage; Sheila Faraj; Katarzyna J. Macura; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W. Partin; Misop Han; H. Ballentine Carter; Trinity J. Bivalacqua; Amanda Blackford; Daniel P. Holt; Robert F. Dannals; George J. Netto; Martin Lodge; Ronnie C. Mease; Martin Pomper; Steve Cho; H. Morgan; James Buchanan; Sidney Kimmel
ASCO Meeting Abstracts | 2015
Daniel Y. Song; Amol K. Narang; S.P. Robertson; A.N. Ram; Pei He; Debasish Sundi; Harleen Singh; Alex DeWeese; Stephanie Honig; Todd R. McNutt; Ashley E. Ross; Trinity J. Bivalacqua; Edward M. Schaeffer; Alan W. Partin; Theodore L. DeWeese; Phuoc T. Tran
Archive | 2011
Sumit Isharwal; Danil V. Makarov; Lori J. Sokoll; Patricia Landis; Cameron Marlow; Jonathan I. Epstein; Alan W. Partin; Robert W. Veltri
Archive | 2008
Ahmed Magheli; Soroush Rais-Bahrami; Bruce J. Trock; Elizabeth B. Humphreys; Alan W. Partin; Misop Han; Mark L. Gonzalgo
American Journal of Hematology/ Oncology | 2007
Stephen J. Freedland; Alan W. Partin; Elizabeth B. Humphreys; Leslie A. Mangold; Patrick C. Walsh